Omthera Pharmaceuticals Inc., of Bedminster, N.J., completed enrollment in a pivotal, Phase III trial of Epanova, its triglyceride-lowering therapy. The trial, designated EVOLVE, is being carried out under a special protocol assessment with the FDA.